206 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
, launch timing, pricing, sales ramp, market share, market exclusivity, research and development expenses, sales and marketing expenses, general … and administrative expenses, effective tax rate and utilization of federal net operating losses, federal research and development expenses and other relevant
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
assets
Deferred tax asset
In-process research and development asset (note 5)
Total non-current assets
Total Assets
Liabilities and Shareholders’ Equity … )
Three-month periods ended
March 31,
Revenues
Expenses:
Research and development
Research tax credits
General and administrative
Total operating expenses
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
and cost of the research and development activities of camlipixant;
our aim to complete the validation of the VitaloJAK for cough frequency measurement … success of current research and development activities;
our achievement of development and commercial milestones, including forecasted preclinical
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
to finance the Company’s operating activities, mainly the research and development activities associated with its product candidate camlipixant (BLU-5937 … share) for the same period in 2022.
Research and Development Expenses: Research and development expenses, net of research tax credits, amounted to US
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
).
“Research Programs” means all research and development programs, pre-clinical and clinical trials, pre-clinical and clinical studies and the results … ), or any research, development, distribution, sale, supply, license, importation, exportation, marketing, co-promotion or manufacturing activities
6-K
EX-99.1
13sw4 fe9gslln3lx
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
o4dn2v oll
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.1
z11 2s6088ql5j563q
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
57fcn8o67diazxviu
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
l3ig6mcuby9hlq
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
F-10
qukikyv1 3iyoxz033j
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
6vk19hl31ajgiz
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.2
fzqles3omhf
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
6w7f40bf2iqfnk uji7c
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
6-K
EX-99.1
dyww7rp975inrak49gh8
18 Jul 22
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
4:05pm
SUPPL
xl6 y33k0vq
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.1
9m8ru4dz0i3fl ebre
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
9640p wybc
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.1
awl7 g7xp3ynv6
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.1
no07efx0kkffv
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm